NLNK up +2.62% percent Today $NLNK High is at 31.4
Post# of 69
Posted On: 11/17/2014 12:20:24 PM
NLNK up +2.62% percent Today $NLNK High is at 31.48 and the Low 30.54 with current volume of 198,076.
Recent News posted below.
Newlink Genetics Corp NLNK other info.
http://investorshangout.com/Newlink-Genetics-...LNK-54895/
NLNK Newlink Genetics Corp Recent Headline News
Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - 13 mins ago
BCRX: 10.16 (+0.09), VSR: 2.97 (-0.02), TKMR: 17.26 (+0.85), NNVC: 3.27 (-0.12), INO: 10.06 (-0.94), CMRX: 33.64 (+1.40), APT: 2.91 (-0.01), HEB: 0.28 (+0.01), SRPT: 15.13 (-0.19), SMED: 4.29 (-0.09), NLNK: 31.43 (+0.89), PLX: 2.11 (+0.02), LAKE: 11.25 (+0.19), NSPH: 0.44 (unch)
NewLink Genetics to Participate in the Upcoming Stifel, Jeffries, and Piper Jaffray Healthcare Conferences
GlobeNewswire - Mon Nov 17, 6:00AM CST
NewLink Genetics Corporation (Nasdaq:NLNK) today announced that it will present at the following conferences:
NLNK: 31.43 (+0.89)
NewLink Genetics elects Dr Thomas P. Monath as chief scientific officer and chief operations officer of its Infectious Disease Division
M2 - Mon Nov 17, 5:59AM CST
Biopharmaceutical company NewLink Genetics (NasdaqGM:NLNK) revealed on Friday the addition of Dr Thomas P. Monath, MD as the chief scientific officer and chief operations officer of its wholly-owned infectious disease division subsidiary, BioProtection Systems.
NLNK: 31.43 (+0.89)
NewLink Genetics Appoints Thomas P. Monath, M.D. to the Position of Chief Scientific and Chief Operations Officer of BioProtection Systems Corporation, Its Infectious Disease Division
GlobeNewswire - Fri Nov 14, 9:06AM CST
NewLink Genetics Corporation (Nasdaq:NLNK) today announced that Thomas P. Monath, M.D. has been appointed Chief Scientific and Chief Operations Officer of its wholly-owned subsidiary, BioProtection Systems Corporation.
NLNK: 31.43 (+0.89)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.57 (+0.50), INCY: 69.17 (-0.37), CLDX: 18.55 (+4.39), NLNK: 31.43 (+0.89), GSK: 45.81 (+0.07), BMY: 58.18 (+0.23), SRNE: 4.21 (-0.02)
Trade-Ideas: NewLink Genetics (NLNK) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Nov 10, 8:56AM CST
Trade-Ideas LLC identified NewLink Genetics (NLNK) as a "dead cat bounce" (down big yesterday but up big today) candidate
NLNK: 31.43 (+0.89)
Critical Alerts For Noodles & Company, NewLink Genetics, Under Armour, JP Morgan Chase and Baidu Released By InvestorsObserver
PR Newswire - Fri Nov 07, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for NDLS, NLNK, UA, JPM and BIDU.
UA: 68.83 (-0.32), BIDU: 243.63 (-6.07), JPM: 60.16 (-0.12), NLNK: 31.43 (+0.89), NDLS: 23.29 (-0.19)
NewLink Genetics' (NLNK) CEO Charles Link on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 1:37PM CST
NLNK: 31.43 (+0.89)
NewLink (NLNK) Stock: Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:10AM CST
NewLink (NLNK) Stock: Moving Average Crossover Alert
NLNK: 31.43 (+0.89)
NewLink Genetics beats by $0.20, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:21AM CST
NLNK: 31.43 (+0.89)
NewLink Genetics Corporation Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 6:08AM CST
NewLink Genetics Corporation (Nasdaq:NLNK), today reported consolidated financial results for the third quarter of 2014 and progress in its clinical and business development programs.
NLNK: 31.43 (+0.89)
Heat Biologics Takes a New Approach to Immunotherapy
ACCESSWIRE - Mon Nov 03, 1:01PM CST
WHITEFISH, MT / ACCESSWIRE / November 3, 2014 / Immunotherapy leverages the body's own immune system to fight off diseases ranging from allergies to cancer. For example, Dendreon Corporation's (NASDAQ: DNDN) PROVENGE therapy takes the patient's own immune cells and reprograms them to attack advanced prostate cancer. These dynamics led to a 22.5% reduced risk of death with just a 1.5% discontinuance rate.
HTBX: 4.21 (-0.23), DNDN: 0.15 (+0.04), NLNK: 31.43 (+0.89), GALE: 1.80 (-0.07)
Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:20PM CDT
Acorda (ACOR) which recently acquired Civitas Therapeutics, is working on reprioritizing its pipeline.
MDVN: 107.33 (+0.43), BIIB: 303.14 (-2.29), NLNK: 31.43 (+0.89), ACOR: 34.07 (+0.60)
Lakeland (LAKE) Stock Soars 30% on Hazmat Suit Sales, Ebola Panic - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Oct 30, 10:16AM CDT
Hazmat suit maker Lakeland industries is soaring again today as sales have been great thanks to the Ebola virus.
JNJ: 108.29 (+0.13), NLNK: 31.43 (+0.89), LAKE: 11.25 (+0.19)
5 Stocks To Consider When Playing Ebola
Belopps Research - at Seeking Alpha - Wed Oct 29, 10:31AM CDT
INO: 10.06 (-0.94), SRPT: 15.13 (-0.19), NLNK: 31.43 (+0.89), TKMR: 17.26 (+0.85), GSK: 45.82 (+0.08)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 14.36 (-0.32), BIIB: 303.14 (-2.29), AMRN: 1.00 (+0.05), UTHR: 125.35 (-0.08), NLNK: 31.43 (+0.89)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 10.06 (-0.94), MRK: 59.57 (+0.50), PFE: 30.05 (-0.29), SRPT: 15.13 (-0.19), NLNK: 31.43 (+0.89), TKMR: 17.26 (+0.85), GSK: 45.82 (+0.08), NVS: 94.40 (+0.45)
CDC issues new guidelines over Ebola
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:10AM CDT
BCRX: 10.16 (+0.09), VSR: 2.97 (-0.02), TKMR: 17.26 (+0.85), NNVC: 3.27 (-0.12), INO: 10.06 (-0.94), CMRX: 33.64 (+1.40), APT: 2.91 (-0.01), HEB: 0.28 (+0.01), SRPT: 15.13 (-0.19), SMED: 4.29 (-0.09), NLNK: 31.43 (+0.89), PLX: 2.11 (+0.02), LAKE: 11.25 (+0.19), NSPH: 0.44 (unch)
Ebola: Search For A Vaccine On The Fast Track
Tony Daltorio - at Seeking Alpha - Mon Oct 27, 11:39AM CDT
JNJ: 108.30 (+0.14), NLNK: 31.43 (+0.89), GSK: 45.82 (+0.08)
NewLink reports November 6
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:16AM CDT
NLNK: 31.43 (+0.89)
Recent News posted below.
Newlink Genetics Corp NLNK other info.
http://investorshangout.com/Newlink-Genetics-...LNK-54895/
NLNK Newlink Genetics Corp Recent Headline News
Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - 13 mins ago
BCRX: 10.16 (+0.09), VSR: 2.97 (-0.02), TKMR: 17.26 (+0.85), NNVC: 3.27 (-0.12), INO: 10.06 (-0.94), CMRX: 33.64 (+1.40), APT: 2.91 (-0.01), HEB: 0.28 (+0.01), SRPT: 15.13 (-0.19), SMED: 4.29 (-0.09), NLNK: 31.43 (+0.89), PLX: 2.11 (+0.02), LAKE: 11.25 (+0.19), NSPH: 0.44 (unch)
NewLink Genetics to Participate in the Upcoming Stifel, Jeffries, and Piper Jaffray Healthcare Conferences
GlobeNewswire - Mon Nov 17, 6:00AM CST
NewLink Genetics Corporation (Nasdaq:NLNK) today announced that it will present at the following conferences:
NLNK: 31.43 (+0.89)
NewLink Genetics elects Dr Thomas P. Monath as chief scientific officer and chief operations officer of its Infectious Disease Division
M2 - Mon Nov 17, 5:59AM CST
Biopharmaceutical company NewLink Genetics (NasdaqGM:NLNK) revealed on Friday the addition of Dr Thomas P. Monath, MD as the chief scientific officer and chief operations officer of its wholly-owned infectious disease division subsidiary, BioProtection Systems.
NLNK: 31.43 (+0.89)
NewLink Genetics Appoints Thomas P. Monath, M.D. to the Position of Chief Scientific and Chief Operations Officer of BioProtection Systems Corporation, Its Infectious Disease Division
GlobeNewswire - Fri Nov 14, 9:06AM CST
NewLink Genetics Corporation (Nasdaq:NLNK) today announced that Thomas P. Monath, M.D. has been appointed Chief Scientific and Chief Operations Officer of its wholly-owned subsidiary, BioProtection Systems Corporation.
NLNK: 31.43 (+0.89)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.57 (+0.50), INCY: 69.17 (-0.37), CLDX: 18.55 (+4.39), NLNK: 31.43 (+0.89), GSK: 45.81 (+0.07), BMY: 58.18 (+0.23), SRNE: 4.21 (-0.02)
Trade-Ideas: NewLink Genetics (NLNK) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Nov 10, 8:56AM CST
Trade-Ideas LLC identified NewLink Genetics (NLNK) as a "dead cat bounce" (down big yesterday but up big today) candidate
NLNK: 31.43 (+0.89)
Critical Alerts For Noodles & Company, NewLink Genetics, Under Armour, JP Morgan Chase and Baidu Released By InvestorsObserver
PR Newswire - Fri Nov 07, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for NDLS, NLNK, UA, JPM and BIDU.
UA: 68.83 (-0.32), BIDU: 243.63 (-6.07), JPM: 60.16 (-0.12), NLNK: 31.43 (+0.89), NDLS: 23.29 (-0.19)
NewLink Genetics' (NLNK) CEO Charles Link on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 1:37PM CST
NLNK: 31.43 (+0.89)
NewLink (NLNK) Stock: Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:10AM CST
NewLink (NLNK) Stock: Moving Average Crossover Alert
NLNK: 31.43 (+0.89)
NewLink Genetics beats by $0.20, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:21AM CST
NLNK: 31.43 (+0.89)
NewLink Genetics Corporation Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 6:08AM CST
NewLink Genetics Corporation (Nasdaq:NLNK), today reported consolidated financial results for the third quarter of 2014 and progress in its clinical and business development programs.
NLNK: 31.43 (+0.89)
Heat Biologics Takes a New Approach to Immunotherapy
ACCESSWIRE - Mon Nov 03, 1:01PM CST
WHITEFISH, MT / ACCESSWIRE / November 3, 2014 / Immunotherapy leverages the body's own immune system to fight off diseases ranging from allergies to cancer. For example, Dendreon Corporation's (NASDAQ: DNDN) PROVENGE therapy takes the patient's own immune cells and reprograms them to attack advanced prostate cancer. These dynamics led to a 22.5% reduced risk of death with just a 1.5% discontinuance rate.
HTBX: 4.21 (-0.23), DNDN: 0.15 (+0.04), NLNK: 31.43 (+0.89), GALE: 1.80 (-0.07)
Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:20PM CDT
Acorda (ACOR) which recently acquired Civitas Therapeutics, is working on reprioritizing its pipeline.
MDVN: 107.33 (+0.43), BIIB: 303.14 (-2.29), NLNK: 31.43 (+0.89), ACOR: 34.07 (+0.60)
Lakeland (LAKE) Stock Soars 30% on Hazmat Suit Sales, Ebola Panic - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Oct 30, 10:16AM CDT
Hazmat suit maker Lakeland industries is soaring again today as sales have been great thanks to the Ebola virus.
JNJ: 108.29 (+0.13), NLNK: 31.43 (+0.89), LAKE: 11.25 (+0.19)
5 Stocks To Consider When Playing Ebola
Belopps Research - at Seeking Alpha - Wed Oct 29, 10:31AM CDT
INO: 10.06 (-0.94), SRPT: 15.13 (-0.19), NLNK: 31.43 (+0.89), TKMR: 17.26 (+0.85), GSK: 45.82 (+0.08)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 14.36 (-0.32), BIIB: 303.14 (-2.29), AMRN: 1.00 (+0.05), UTHR: 125.35 (-0.08), NLNK: 31.43 (+0.89)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 10.06 (-0.94), MRK: 59.57 (+0.50), PFE: 30.05 (-0.29), SRPT: 15.13 (-0.19), NLNK: 31.43 (+0.89), TKMR: 17.26 (+0.85), GSK: 45.82 (+0.08), NVS: 94.40 (+0.45)
CDC issues new guidelines over Ebola
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:10AM CDT
BCRX: 10.16 (+0.09), VSR: 2.97 (-0.02), TKMR: 17.26 (+0.85), NNVC: 3.27 (-0.12), INO: 10.06 (-0.94), CMRX: 33.64 (+1.40), APT: 2.91 (-0.01), HEB: 0.28 (+0.01), SRPT: 15.13 (-0.19), SMED: 4.29 (-0.09), NLNK: 31.43 (+0.89), PLX: 2.11 (+0.02), LAKE: 11.25 (+0.19), NSPH: 0.44 (unch)
Ebola: Search For A Vaccine On The Fast Track
Tony Daltorio - at Seeking Alpha - Mon Oct 27, 11:39AM CDT
JNJ: 108.30 (+0.14), NLNK: 31.43 (+0.89), GSK: 45.82 (+0.08)
NewLink reports November 6
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:16AM CDT
NLNK: 31.43 (+0.89)
(0)
(0)Lumos Pharma, Inc. (LUMO) Stock Research Links
Scroll down for more posts ▼